Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives

J Am Coll Cardiol. 2021 Aug 17;78(7):737-751. doi: 10.1016/j.jacc.2021.06.022.

Abstract

Although some progress has been made in the last 3 decades to increase the number of women in clinical cardiology trials, review of recent cardiovascular literature demonstrates that women and underrepresented minority women are still underrepresented in most clinical cardiology trials. This is especially notable in trials of patients with coronary artery disease, heart failure with reduced ejection fraction, and arrhythmia studies, especially those involving devices and procedures. Despite the call from National Institutes of Health, Food and Drug Administration, Institute of Medicine, and various professional societies, the gap remains. This paper seeks to identify the barriers for low enrollment and retention from patient, clinician, research team, study design, and system perspectives, and offers recommendations to improve recruitment and retention in the current era.

Keywords: cardiology trials; cardiovascular disease; congestive heart failure; underrepresented minority; women.

Publication types

  • Review

MeSH terms

  • Ageism
  • Animals
  • Cardiology*
  • Cardiovascular Diseases / therapy*
  • Clinical Trials as Topic*
  • Female
  • Humans
  • Leadership
  • Male
  • Patient Participation*
  • Pregnancy
  • Sex Characteristics
  • Women*